Table 2.
Cellular and humoral immune responses following SARS-CoV-2 vaccination at T1 and T2.
| Vaccines (mRNA- and vector-based) |
p-value | ||
|---|---|---|---|
| T1 | T2 | ||
| IL-2, SI | 2.4 [1.5–4.5] (n = 33) |
1.6 [1.0–4.7] (n = 33) |
0.93 |
| IFN-γ, SI | 3 [1–5] (n = 43) |
3 [1–7] (n = 43) |
0.85 |
| SARS-CoV-2 anti-spike IgG, AU/mL (Abbott array) | 3517 [1070–11,164] (n = 48) |
2240 [756–7687] (n = 48) |
<0.001 |
| SARS-CoV-2 anti-spike IgG, % (GenID assay) | 79.5 [68.5–92.2] (n = 48) |
84.5 [58–92.7] (n = 48) |
0.37 |
Values are the median [interquartile range]. Bolded p-values denote statistical significance at the p < 0.05 level. We conducted analyses of patients who had valid measurements at both time points.
IFN-γ, interferon-γ; IgG, immunoglobulin G; IL-2, interleukin-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; T1, timepoint 1; T2, timepoint 2.